Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.21 Analyst target: $11.50 Upside: 854.36%
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development and commercialization of drugs for the treatment of cancer. The company is headquartered in Florham Park, New Jersey.
See the full interactive analysis & chart →Informational only — not investment advice.